ChomiX Biotech
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A preclinical-stage biotech developing novel small molecule drugs for oncology and immunology using a proprietary chemical biology platform.
OncologyImmunology
Technology Platform
A proprietary chemical biology and screening platform for the discovery and optimization of novel small molecule drug candidates.
Opportunities
Potential to out-license promising preclinical assets to larger partners for clinical development and commercialization.
Risk Factors
High risk of preclinical failure and significant challenges in securing funding to advance programs into costly clinical trials.
Competitive Landscape
Faces intense competition from numerous global and Chinese biotechs and pharmas also pursuing novel small molecules in oncology and immunology.